# A computational pipeline to discover potential cross-reactive antibodies: a case study on coronavirus

**Authors:** Li Ye, Mengdie Hu, Yuan Wang, Zihao Li, Yewei Cun, Kailin Tang, Zhiwei Cao

PMC · DOI: 10.3389/fcimb.2026.1692727 · Frontiers in Cellular and Infection Microbiology · 2026-02-09

## TL;DR

This paper introduces a computational pipeline to identify cross-reactive antibodies for coronaviruses, offering a faster alternative to traditional methods.

## Contribution

The novel contribution is an integrative computational pipeline for predicting cross-reactive epitopes and prioritizing cross-reactive antibodies.

## Key findings

- The pipeline predicted candidate cross-reactive antibodies for five coronavirus antigens, including SARS-CoV-2 variants and SARS-CoV.
- 45% of the top 20 predicted candidates were validated as cross-reactive in CoV-AbDab.
- Experimentally confirmed cross-reactive antibodies like P17, BG7-15, and Beta-54 were identified with strong binding affinities.

## Abstract

Cross-reactive antibody (crAb), which recognizes conserved viral epitopes across diverse strains, has emerged as powerful tools for diagnostics, therapeutic targeting, and pandemic preparedness. Yet conventional crAb discovery primarily relies on hybridoma technology and phage display which are time-consuming and labor-intensive.

Here, we present an integrative computational pipeline that leverages conformational epitope prediction and epitope immunogenic similarity analysis to compute cross-reactive epitopes, so as to prioritize potential crAbs undisclosed before.

Taking coronavirus as an example, we demonstrate that this pipeline successfully predicted candidate crAbs for five coronavirus antigens, including SARS-CoV-2 variants (WT, Beta, Omicron B.1, XBB.1.5) and one SARS-CoV variant. Out of Top20 predicted candidates, 45% were validated in CoV-AbDab as cross-reactive across coronavirus variants, including experimentally confirmed crAbs such as P17 (IC50 = 0.165 ng/mL against SARS-CoV-2 WT), BG7-15 (IC50 = 16 ng/mL against SARS-CoV-2 WT), and Beta-54 (IC50 = 1 ng/mL against Gamma variant).

Though in pilot-study, this pipeline might serve as a scalable and efficient strategy for rapidly prioritizing potential crAbs in research of infectious disease.

## Linked entities

- **Diseases:** SARS-CoV-2 (MONDO:0100096)

## Full-text entities

- **Genes:** IGHV1-18 (immunoglobulin heavy variable 1-18) [NCBI Gene 28468] {aka IGHV118}, S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}, ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}
- **Diseases:** infectious disease (MESH:D003141), CD-HIT (MESH:D003424), COVID-19 (MESH:D000086382)
- **Chemicals:** BG7-15 (-), water (MESH:D014867)
- **Species:** Dengue virus (no rank) [taxon 12637], Sarbecovirus (subgenus) [taxon 2509511], Coronaviridae (family) [taxon 11118], Homo sapiens (human, species) [taxon 9606], Gammacoronavirus (genus) [taxon 694013], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Severe acute respiratory syndrome-related coronavirus (no rank) [taxon 694009], Zika virus (no rank) [taxon 64320], Human coronavirus HKU1 (no rank) [taxon 290028], Middle East respiratory syndrome-related coronavirus (no rank) [taxon 1335626], Human coronavirus OC43 (no rank) [taxon 31631], H3N2 subtype (serotype) [taxon 119210], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** AUC of 0, G446S
- **Cell lines:** HL1144 — Homo sapiens (Human), Transformed cell line (CVCL_9E17), HL425 — Mus musculus (Mouse), Hybridoma (CVCL_LB64), BG7-15 — Homo sapiens (Human), Ovarian adenocarcinoma, Cancer cell line (CVCL_6570), HL806 — Homo sapiens (Human), Galactosialidosis, Finite cell line (CVCL_CX43), Pangolin-GD — Homo sapiens (Human), Gaucher disease, Induced pluripotent stem cell (CVCL_YC29), HL4340 — Homo sapiens (Human), Zellweger syndrome, Finite cell line (CVCL_N017), HL8308 — Homo sapiens (Human), Transformed cell line (CVCL_JC04), HL1145 — Homo sapiens (Human), Transformed cell line (CVCL_9E18), HL193 — Homo sapiens (Human), Finite cell line (CVCL_2492), HL226 — Homo sapiens (Human), Glycogen storage disease type III, Finite cell line (CVCL_1F02)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12926425/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12926425/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC12926425/full.md

---
Source: https://tomesphere.com/paper/PMC12926425